Moderna advances combo vaccine for flu and COVID-19 with trials starting in March Pharmaceutical companies gear up to tackle ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) fell 8.9% on Wednesday after UBS Group lowered their price target on the stock from $108.00 to $96.00. UBS Group currently has a buy rating on the stock.

Moderna, Inc. has a 12 month low of $35.80 and ... and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex ...

Not many people had heard of human metapneumovirus, or HPMV, until a surge of recent cases in China made headlines.

Five years after the first cases of COVID-19, reports of hMPV, an obscure respiratory virus in China may understandably raise ...

Moderna cuts 2025 sales forecast by $1 bln on ... when asked about the rising cases of the human metapneumovirus (HMPV) in China. China in contact with WHO on respiratory diseases, foreign ...

Kashmir's leading scientist and gastroenterologist, Prof M Sultran Khuroo writes about the evolution of the Human ...

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.

Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads ...

Meta Platforms is ending fact-checking and speech restrictions across Facebook and Instagram, as Chief Executive Mark Zuckerberg embraces a second Trump presidency. Starting in the U.S., Meta will ...

Moderna (MRNA) shares are plunging after the company cut its 2025 sales guidance. A number of retailers updated their quarterly guidance, including Lululemon (LULU), Macy's (M), and Abercrombie ...

But scientists at Moderna are in the late stages of testing what could be the first such shot, using mRNA technology against the virus. Here’s what to know about norovirus and where things stand ...